분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-10-31 06:30:40 , Hit : 1347
 As the RNA World Turns (Either Way, with Cross-Chiral Enzyme)

GEN News Highlights
More »
Oct 30, 2014

        
        Evolution in a test tube may have recapitulated an evolutionary phase dating back to the very origins of life. During this phase, a simpler, pre-DNA time known as “RNA world,” life acquired one of its chemical prerequisites—the ability to self-replicate. That is, RNA strands started to assemble copies of themselves. Yet it has been unclear how this could have happened.
Virtually all the RNA we know has just one chirality, or handedness. But self-replicating RNA in the RNA world most likely had to contend with both left- and right-handed RNA nucleotide building blocks. Any strand of RNA that gathered stray nucleotides onto itself would have eventually incorporated an RNA nucleotide of the opposite handedness—which would have blocked further assembly of that copy.
One way life could have solved this conundrum, suggests researchers at The Scripps Research Institute (TSRI), would have been a cross-chiral RNA polymerase ribozyme. It would, as expected, have used an original RNA strand as a reference or template from which to knit together a copy strand of RNA. However, the copy would have opposite handedness. That is, the copy would not have been identical to the original. It would have been mirrored the original, rather like a left hand appears to mirror a right hand.
No one had ever made or even tried to make a ribozyme that worked cross-chirally, on opposite-handed RNA. But that did not deter researchers led by Gerald F. Joyce, Ph.D., professor in TSRI’s Departments of Chemistry and Cell and Molecular Biology and director of the Genomics Institute of the Novartis Research Foundation. These researchers synthesized such a ribozyme by using a technique called “test-tube evolution.”
A postdoc in Dr. Joyce’s group named Jonathan T. Sczepanski started with a soup of about a quadrillion (1015) short RNA molecules. Their sequences were essentially random, and all were of right-handed chirality. “We set it up so that the molecules that could catalyze a joining reaction with left-handed RNA could be pulled out of solution and then amplified.” Dr. Sczepanski said.
After just 10 of these selection-and-amplification rounds, the researchers had a strong candidate ribozyme. They then expanded the size of its core region, put it through six more selection rounds and trimmed the extraneous nucleotides. The result: an 83-nucleotide ribozyme that was only moderately sequence-specific and could reliably knit a test segment of left-handed RNA to a template—about a million times faster than would have happened without enzyme assistance.

        The team also showed that the new ribozyme could work without hindrance even when same-handed RNA nucleotides were present. In a last test, the new ribozyme successfully catalyzed the assembly of 11 segments of RNA to make a complete copy of its left-handed counterpart ribozyme, which in turn was able to join segments of right-handed RNA.
The researchers are now working to put the right-handed ribozyme (and by implication its left-handed partner) through more selection rounds, so that it can mediate the full replication of RNA, with essentially no sequence-dependence. That would make it a true general-purpose RNA-replication enzyme, capable in principle of turning a primordial nucleotide soup into a vast biosphere.
The scientists reported their results October 29 in Nature, in an article entitled, “A cross-chiral RNA polymerase ribozyme.”
“Cross-chiral replication does not require the D- and L-enzymes to have the same sequence, and even if initiated with enzymes of the same sequence, the two would probably soon drift apart,” the authors wrote. “If early life did entail the cross-chiral polymerization of RNA, then there would have been an era when both sides of the mirror were indispensable. Subsequently, however, a key evolutionary innovation may have arisen on one side of the mirror, for example, the invention of instructed L-polypeptide synthesis by D-RNA. Then the other side of the mirror could go dark, leaving biology to follow a homochiral path.”
To enjoy more articles like this from GEN, click here to subscribe now!







987   인간과 생쥐 유전체의 유사성과 차이점  이성욱 2014/11/25 1923
986   Cost to Develop a Drug More Than Doubles to $2.56 Billion  이성욱 2014/11/21 1128
985   세균과 싸우도록 자극하면, 바이러스까지도 물리치는 세포  이성욱 2014/11/20 1492
984   Gilead wins European approval of next-generation hepatitis C drug  이성욱 2014/11/20 1159
983   [바이오토픽] 표준 인간 게놈지도의 갭을 메워라: 플래티넘 게놈지도 탄생  이성욱 2014/11/19 1594
982   종양 내에서 T 세포 면역에 핵심적인 항원제시 세포  이성욱 2014/11/17 1659
981   AbbVie, Enanta drug shows potential in hep C genotype 4 patients  이성욱 2014/11/15 1186
980   Gilead hepatitis C drug highly effective in cirrhosis patients  이성욱 2014/11/14 1066
979   새로운 HIV/AIDS 치료법 개발  이성욱 2014/11/14 1468
978   간 이식 환자들의 C형 간염을 완치시킨 새로운 치료법  이성욱 2014/11/14 1665
977   간 이식 환자들의 C형 간염에 효과적인 병용 요법  이성욱 2014/11/13 1607
976   J&J Wins U.S. Approval for Hepatitis C Combo With Gilead  이성욱 2014/11/07 1523
975   에볼라에 대한 반응과 유전적 요인  이성욱 2014/11/04 1279
974   실험실에서 만든 인공위장  이성욱 2014/11/04 1222
973   거울이미지 RNA효소와 생명이 기원  이성욱 2014/11/03 1493
972   어떻게 복잡한 생명은 진화했는가?  이성욱 2014/10/31 1601
971   인간 녹아웃을 연구하는 유전학자들  이성욱 2014/10/31 1562
  As the RNA World Turns (Either Way, with Cross-Chiral Enzyme)  이성욱 2014/10/31 1347
969   암의 우군-엑소좀(exosome)  이성욱 2014/10/29 2788
968   이웃의 정상세포를 감염시키는 암세포  이성욱 2014/10/27 1464

[이전 10개] [1]..[11][12][13][14] 15 [16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN